Pembrolizumab 200 mg IV q3w — r/r cHL post-BV (KEYNOTE-204 schedule)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-PEMBROLIZUMAB |
|---|
| ID | REG-PEMBROLIZUMAB-CHL |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-HODGKIN-2024 SRC-NCCN-BCELL-2025 |
Notes
KEYNOTE-204 trial (Kuruvilla 2021): r/r cHL post-BV (n=304) — pembrolizumab vs BV — mPFS 13.2 vs 8.3 mo (HR 0.65, p=0.00271); CR rate 24.5% vs 24.2% (similar); PFS benefit predominantly from durable PR/SD plateau. Established 2L+ for r/r cHL post-BV; also useful in BV-naïve r/r cHL based on KEYNOTE-087. cHL has high PD-L1 expression (9p24.1 amplification) → strong checkpoint responses. Bridge to alloSCT in fit transplant-eligible responders per SCT-eligible practice. Combined with BV (BV+pembro) being studied as 1L in Hodgkin Lymphoma Study Group (HD21-style) combinations.
Used By
Indication
IND-CHL-2L-PEMBROLIZUMAB- IND-CHL-2L-PEMBROLIZUMAB